Comparing the current results to its competitors, Relay Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by -48.3 %, despite the revenue increase by the most of its competitors of 14.12 %, recorded in the same quarter.
June 5, 2024
Relay Therapeutics and Pfizer Collaborate on Groundbreaking Clinical Trial for PI3K-Mutated HR+/HER2- Metastatic Breast CancerIn an exciting development in the fight against metastatic breast cancer, Relay Therapeutics has announced a clinical trial collaboration with pharmaceutical giant Pfizer. This joint effort aims to explore the potential benefits of combining Atirmociclib, RLY-2608, and Fulvestrant in treating patients with PI3K-mutated HR+/HER2- metastatic breast cancer. The clinical trial, scheduled to commence by the end of 2024, marks a significant step forward in the management and treatment of this challenging form of cancer. The Rationale Behind the TrialThe decision to evaluate this specific c...
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
C4 Therapeutics Inc operates on a business model that focuses on developing novel therapies using their proprietary Degronimid™ platform, designed to selectively target and degrade disease-causing proteins. This approach potentially offers a new avenue for treating various diseases by harnessing the body's natural protein degradation machinery.
The business model of Blueprint Medicines Corporation revolves around the development and commercialization of precision therapies for patients with genomically defined cancers and rare diseases. They actively pursue a strategy of genomically targeted drug discovery and development, utilizing advanced technologies and clinical expertise to bring potentially life-changing treatments to market. The company focuses on creating value through strategic collaborations, licensing agreements, and the commercialization of their innovative therapies.
Black Diamond Therapeutics Inc's business model is centered around developing targeted therapies for cancer patients by leveraging its proprietary platform and expertise in precision medicine.
Argenx is a biopharmaceutical company that utilizes its proprietary antibody discovery platform to develop and commercialize transformative antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Their business model focuses on discovering and developing novel antibodies, partnering with pharmaceutical companies for clinical development, and retaining rights to commercialize the therapies in specific regions.
Sources:
Relay Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Relay Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
